
Adlai Nortye licenses shelved Novartis compound buparlisib to develop combo cancer therapies
Executive Summary
Adlai Nortye licensed exclusive worldwide development and commercialization rights to Novartis Pharma AG's buparlisib (BKM120) for all therapeutic, prophylactic, or diagnostic uses, except for certain rights Novartis retains.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com